Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerhard Wolber

Showing results (191-200 of 213) with videos related to

Pageof 22
Sort By:
Biochemical Pharmacology|December 25, 2012
Design, synthesis, inhibition studies, and molecular modeling of pepstatin analogues addressing different secreted aspartic proteinases of Candida albicansCosimo D Cadicamo, Jérémie Mortier, Gerhard Wolber, et al.
European Journal of Medicinal Chemistry|August 23, 2014
Design, synthesis and molecular docking study of novel quinoxalin-2(1H)-ones as anti-tumor active agents with inhibition of tyrosine kinase receptor and studying their cyclooxygenase-2 activityShadia A Galal, Sarah H M Khairat, Fatma A F Ragab, et al.
Plos One|December 11, 2012
Identification of PPARgamma partial agonists of natural origin (I): development of a virtual screening procedure and in vitro validationLaura Guasch, Esther Sala, Anna Castell-Auví, et al.
Molecular Pharmacology|January 13, 2010
Computer-aided discovery, validation, and mechanistic characterization of novel neolignan activators of peroxisome proliferator-activated receptor gammaNanang Fakhrudin, Angela Ladurner, Atanas G Atanasov, et al.
Journal of Medicinal Chemistry|January 16, 2009
Discovery of novel CB2 receptor ligands by a pharmacophore-based virtual screening workflowPatrick Markt, Clemens Feldmann, Judith Maria Rollinger, et al.
European Journal of Medicinal Chemistry|September 10, 2013
Design, synthesis and structure-activity relationship of novel quinoxaline derivatives as cancer chemopreventive agent by inhibition of tyrosine kinase receptorShadia A Galal, Ahmed S Abdelsamie, Salwa M Soliman, et al.
Bioorganic & Medicinal Chemistry|October 22, 2011
Pharmacophore-based discovery of FXR-agonists. Part II: identification of bioactive triterpenes from Ganoderma lucidumUlrike Grienke, Judit Mihály-Bison, Daniela Schuster, et al.
Molecular Cancer Therapeutics|September 20, 2013
Isolation of a novel thioflavin S-derived compound that inhibits BAG-1-mediated protein interactions and targets BRAF inhibitor-resistant cell linesMarion Enthammer, Emmanouil S Papadakis, Maria Salomé Gachet, et al.
European Journal of Medicinal Chemistry|January 7, 2012
Synthesis and biological assessment of novel 2-thiazolylhydrazones and computational analysis of their recognition by monoamine oxidase BSimona Distinto, Matilde Yáñez, Stefano Alcaro, et al.
EMBO Molecular Medicine|June 14, 2024
Disrupting TSLP-TSLP receptor interactions via putative small molecule inhibitors yields a novel and efficient treatment option for atopic diseasesPartho Protim Adhikary, Temilolu Idowu, Zheng Tan, et al.
Pageof 22

Showing results (191-200 of 213) with videos related to

Sort By:
Pageof 22
Biochemical Pharmacology|December 25, 2012
Design, synthesis, inhibition studies, and molecular modeling of pepstatin analogues addressing different secreted aspartic proteinases of Candida albicansCosimo D Cadicamo, Jérémie Mortier, Gerhard Wolber, et al.
European Journal of Medicinal Chemistry|August 23, 2014
Design, synthesis and molecular docking study of novel quinoxalin-2(1H)-ones as anti-tumor active agents with inhibition of tyrosine kinase receptor and studying their cyclooxygenase-2 activityShadia A Galal, Sarah H M Khairat, Fatma A F Ragab, et al.
Plos One|December 11, 2012
Identification of PPARgamma partial agonists of natural origin (I): development of a virtual screening procedure and in vitro validationLaura Guasch, Esther Sala, Anna Castell-Auví, et al.
Molecular Pharmacology|January 13, 2010
Computer-aided discovery, validation, and mechanistic characterization of novel neolignan activators of peroxisome proliferator-activated receptor gammaNanang Fakhrudin, Angela Ladurner, Atanas G Atanasov, et al.
Journal of Medicinal Chemistry|January 16, 2009
Discovery of novel CB2 receptor ligands by a pharmacophore-based virtual screening workflowPatrick Markt, Clemens Feldmann, Judith Maria Rollinger, et al.
European Journal of Medicinal Chemistry|September 10, 2013
Design, synthesis and structure-activity relationship of novel quinoxaline derivatives as cancer chemopreventive agent by inhibition of tyrosine kinase receptorShadia A Galal, Ahmed S Abdelsamie, Salwa M Soliman, et al.
Bioorganic & Medicinal Chemistry|October 22, 2011
Pharmacophore-based discovery of FXR-agonists. Part II: identification of bioactive triterpenes from Ganoderma lucidumUlrike Grienke, Judit Mihály-Bison, Daniela Schuster, et al.
Molecular Cancer Therapeutics|September 20, 2013
Isolation of a novel thioflavin S-derived compound that inhibits BAG-1-mediated protein interactions and targets BRAF inhibitor-resistant cell linesMarion Enthammer, Emmanouil S Papadakis, Maria Salomé Gachet, et al.
European Journal of Medicinal Chemistry|January 7, 2012
Synthesis and biological assessment of novel 2-thiazolylhydrazones and computational analysis of their recognition by monoamine oxidase BSimona Distinto, Matilde Yáñez, Stefano Alcaro, et al.
EMBO Molecular Medicine|June 14, 2024
Disrupting TSLP-TSLP receptor interactions via putative small molecule inhibitors yields a novel and efficient treatment option for atopic diseasesPartho Protim Adhikary, Temilolu Idowu, Zheng Tan, et al.
Pageof 22